lysine has been researched along with imatinib mesylate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beghini, A; Bellini, M; Cairoli, R; Colapietro, P; Larizza, L; Magnani, I; Morra, E | 1 |
| Bartella, V; Bussolari, R; Calabretta, B; Candini, O; Cesi, V; Corradini, F; Pani, E | 1 |
| Balabanov, S; Bokemeyer, C; Brassat, U; Brümmendorf, TH; Copland, M; Gontarewicz, A; Hartmann, U; Hauber, I; Hauber, J; Holyoake, TL; Kammer, W; Kanz, L; Nordheim, A; Priemer, M; Schwarz, G; Wilhelm, T; Ziegler, P | 1 |
| Bastian, BC; Bauer, J; Lutzky, J | 1 |
| Dubey, KD; Ojha, RP | 1 |
| Bassan, R; Bussini, A; Castagnetti, F; Gnani, A; Intermesoli, T; Rosti, G; Soverini, S; Spinelli, O | 1 |
6 other study(ies) available for lysine and imatinib mesylate
| Article | Year |
|---|---|
STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.
Topics: Antineoplastic Agents; Asparagine; Benzamides; Cell Line, Tumor; Humans; Imatinib Mesylate; Lysine; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction | 2005 |
Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants.
Topics: Alanine; Animals; Apoptosis; Benzamides; Blotting, Northern; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Genes, Dominant; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leucine; Lithium Chloride; Lysine; Mice; Mice, Inbred C57BL; Mutation; Phosphatidylinositol 3-Kinases; Piperazines; Plasmids; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myb; Pyrimidines; Retroviridae; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Time Factors; Transcription, Genetic; Transfection; Ubiquitin | 2005 |
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Down-Regulation; Drug Delivery Systems; Drug Synergism; Eukaryotic Translation Initiation Factor 5A; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Lysine; Peptide Initiation Factors; Piperazines; Protein Processing, Post-Translational; Proteomics; Pyrimidines; RNA-Binding Proteins | 2007 |
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.
Topics: Aged; Amino Acid Substitution; Anus Neoplasms; Benzamides; Dose-Response Relationship, Drug; Female; Glutamic Acid; Humans; Imatinib Mesylate; Intestinal Mucosa; Lysine; Melanoma; Neoplasm Metastasis; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction | 2008 |
Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex.
Topics: Alanine; Benzamides; Binding Sites; Glutamic Acid; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ligands; Lysine; Molecular Dynamics Simulation; Mutagenesis; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Salts; Thermodynamics | 2012 |
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Dasatinib; Female; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysine; Mutation, Missense; Phenylalanine; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome | 2012 |